CYP19A1 and breast cancer: Taking sequential treatment, analyzing patients from the time of randomization between continuing tamoxifen and switching to an aromatase inhibitor, the recurrence rate was reduced from 8.1 to 5% at 3 years of follow-up from randomization with a significant 0.7% reduction in breast cancer mortality among those patients receiving an aromatase inhibitor.